Pictet Asset Management Holding SA lifted its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) by 19.6% in the third quarter, according to its most recent filing with the SEC. The firm owned 3,313,062 shares of the company’s stock after acquiring an additional 542,361 shares during the period. Pictet Asset Management Holding SA’s holdings in Taysha Gene Therapies were worth $16,135,000 as of its most recent filing with the SEC.
Other institutional investors have also made changes to their positions in the company. Privium Fund Management B.V. boosted its position in shares of Taysha Gene Therapies by 17.1% during the 3rd quarter. Privium Fund Management B.V. now owns 232,900 shares of the company’s stock valued at $1,134,000 after acquiring an additional 34,000 shares in the last quarter. Alps Advisors Inc. increased its stake in Taysha Gene Therapies by 48.6% in the third quarter. Alps Advisors Inc. now owns 431,669 shares of the company’s stock valued at $2,102,000 after acquiring an additional 141,126 shares during the period. Chicago Partners Investment Group LLC raised its position in Taysha Gene Therapies by 1.8% in the third quarter. Chicago Partners Investment Group LLC now owns 226,379 shares of the company’s stock worth $896,000 after purchasing an additional 4,032 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Taysha Gene Therapies in the third quarter worth about $81,000. Finally, ProShare Advisors LLC raised its position in Taysha Gene Therapies by 9.8% in the third quarter. ProShare Advisors LLC now owns 44,800 shares of the company’s stock worth $218,000 after purchasing an additional 3,983 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.
Taysha Gene Therapies Stock Performance
NASDAQ:TSHA opened at $4.21 on Friday. Taysha Gene Therapies, Inc. has a 1 year low of $3.45 and a 1 year high of $7.30. The firm has a 50 day moving average of $4.52 and a 200-day moving average of $5.28. The company has a current ratio of 17.76, a quick ratio of 17.76 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.37 billion, a P/E ratio of -10.02 and a beta of 1.36.
Analyst Upgrades and Downgrades
A number of brokerages have commented on TSHA. The Goldman Sachs Group raised their price target on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, September 21st. Finally, Wolfe Research started coverage on Taysha Gene Therapies in a research note on Thursday, September 17th. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $12.77.
Get Our Latest Stock Report on TSHA
Taysha Gene Therapies Company Profile
Taysha Gene Therapies is a biotechnology company focused on developing gene therapies for rare, genetically driven diseases. Based in Dallas, Texas, the company was founded in 2019 and has built its programs around adeno-associated virus delivery technology. The company’s lead program, TSHA-102, is an investigational gene therapy being developed for Rett syndrome, a rare neurological disorder. Taysha’s research has also included gene therapy programs for other rare diseases, including giant axonal neuropathy.
Further Reading
- Five stocks we like better than Taysha Gene Therapies
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Want to see what other hedge funds are holding TSHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report).
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
